30 results about "Visual acuity loss" patented technology

Nucleic acid vectors encoding light-gated cation-selective membrane channels, in particular channelrhodopsin-2 (Chop2), converted inner retinal neurons to photosensitive cells in photoreceptor-degenerated retina in an animal model. Such treatment restored visual perception and various aspects of vision. A method of restoring light sensitivity to a retina of a subject suffering from vision loss due to photoreceptor degeneration, as in retinitis pigmentosa or macular degeneration, is provided. The method comprises delivering to the subject by intravitreal or subretinal injection, the above nucleic acid vector which comprises an open reading frame encoding a rhodopsin, to which is operatively linked a promoter and transcriptional regulatory sequences, so that the nucleic acid is expressed in inner retinal neurons. These cells, normally light-insensitive, are converted to a light-sensitive state and transmit visual information to the brain, compensating for the loss, and leading to restoration of various visual capabilities.

A nutritional supplement composition that promotes visual health and reduces or reverses visual acuity loss by a reduced Vitamin E content from standard supplements with the addition of taurine, omega-3 fatty acids, and non proform Vitamin A carotenoids including lutein and zeaxanthin. The essential ingredients of the nutritional or dietary supplements are Vitamin C, no more than 300 IUs of Vitamin E, Vitamin A at least a portion of which is provided in the form of a proform Vitamin A carotenoid, omega-3 fatty acids, and non proform Vitamin A carotenoids including lutein and / or zeaxanthin. The essential ingredients are provided in a form suitable of oral ingestion or other forms of administration in one or more doses per day.

A laser system that includes a diode pump source. A frequency doubled solid state visible laser is pumped by the diode pump source and produces a pulsed laser output with a train of pulses. Resources provide instructions for the creation of the pulsed output, with on and off times that provide for substantial confinement of thermal effects at a target site. This laser system results in tissue specific photoactivation (or TSP) without photocoagulation damage to any of the adjacent tissues and without causing full thickness retinal damage and the associated vision loss.

A method and apparatus for providing microcurrent stimulation (MSC) therapy. In accordance with the present invention, it has been determined that the application of microcurrent signals at particular frequencies to the eye for particular periods of time stabilizes and even improves conditions of macular degeneration and other ocular diseases. Experimental data from clinical trials shows that results of persons who underwent therapy are at least better than placebo, and that the therapy is safe and efficacious. In fact, experimental data from clinical trials showed that approximately 98% of the patients who underwent the MCS therapy of the invention experienced either stabilization or improvement of macular degeneration within one year of starting therapy. Of this percentage, approximately 65% of the patients subjected to the MCS therapy experienced improved vision, while approximately 32% experienced stabilization of macular degeneration (i.e., no further loss of vision).

A visual defect simulation system receives a functional field map produced by an MRI system that relates locations in a patient's brain to locations in the patient's field of view. Planned medical operations are indicated at locations in the patient's brain and any resulting vision loss is simulated with a revised functional field map. A scene is displayed and an impairment overlay is produced from the revised functional field map that blocks the scene at locations corresponding to simulated vision loss. The overlay is translated over the scene in response to viewer eye movements detected by a vision-tracking system to present a real-time simulation of the resulting vision loss.

A nutritional or dietary supplement composition that promotes retinal health through the prevention and / or treatment of visual acuity loss by reducing the risk of developing age-related macular degeneration in persons with early age-related macular degeneration. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, micronutrients and other antioxidants. The essential ingredients are provided in an oral dosage. The composition is taken in the form of one or two tablets or capsules daily.

A visual distortion test is disclosed using a sequence of binary interactions with a mobile device, in which segments of the grid having no distortions are eliminated, and the segments with distortions are divided into smaller segments for further analysis. The test can quantify the visual distortion using a decreased number of steps, compared to sequential analysis of all the segments of the grid. The binary interaction or input to the mobile device is also easier for patients than graphic interactions with a conventional Amsler Grid. Early detection of changes in the visual distortion can enable the healthcare provider to individualize treatment, helping to prevent vision loss while minimizing visits to the office, discomfort, and expense.

Compositions for maintaining, strengthening, improving, or promoting eye health comprise α-lipoic acid, ascorbic acid, and α-tocopherol, or pharmaceutical equivalents thereof. The compositions are useful to prevent, stabilize, reverse and / or treat visual acuity loss in subjects having, or being at risk of developing, an ocular disease. The compositions can further comprise one or more other antioxidants, beneficial minerals, and / or nutritional or dietary materials.

Because vision loss in most forms of glaucoma is related to elevated IOP, most glaucoma treatment protocols are concerned with lowering IOP by increasing aqueous humor outflow. The invention utilizes electromagnetic radiation to create retraction in the iris tissue, thereby (a) reducing convexity and enlarging the drainage angle and thus the area of the anterior chamber, (b) reducing contact between the zonule fibers and the iris pigment epithelium, (c) applying greater tension to both the TM and uveoscleral outflow pathways, thereby enlarging those pathways and increasing outflow.

The present invention provides a reading test to measure vision loss. In one embodiment, the vision loss is due to disease progression. The tests are useful in evaluating the effects of intervention in vision deterioration. The tests are non-invasive, simple, quick, sensitive, reproducible, and easy to administer. The tests measure the subject's reading speed and accuracy under defined conditions of illumination and contrast. The results of these tests may be used to determine if treatment of a disease should be initiated, terminated, altered, or remain unchanged.

A nutritional supplement composition that promotes visual health and reduces or reverses visual acuity loss by a reduced Vitamin E content from standard supplements with the addition of taurine, omega-3 fatty acids, and non proform Vitamin A carotenoids including lutein and zeaxanthin. The essential ingredients of the nutritional or dietary supplements are Vitamin C, no more than 300 IUs of Vitamin E, Vitamin A at least a portion of which is provided in the form of a proform Vitamin A carotenoid, omega-3 fatty acids, and non proform Vitamin A carotenoids including lutein and / or zeaxanthin. The essential ingredients are provided in a form suitable of oral ingestion or other forms of administration in one or more doses per day.

Novel vision monitoring and diagnostic testing tools and help-seeking enablers that may be used individually or in combination as vision monitoring and diagnostic testing systems that improve patients' ability to recognize onset and progression of visual changes over time, so that the identification of acute or chronic visual conditions may be improved and accelerated, which drives earlier help-seeking behavior by the patient, which enables earlier clinical diagnosis by an eye care specialist and therefore earlier treatment and therefore reduced likelihood of severe vision loss.

Novel vision monitoring and diagnostic testing tools and help-seeking enablers that may be used individually or in combination as vision monitoring and diagnostic testing systems that improve patients' ability to recognize onset and progression of visual changes over time, so that the identification of acute or chronic visual conditions may be improved and accelerated, which drives earlier help-seeking behavior by the patient, which enables earlier clinical diagnosis by an eye care specialist and therefore earlier treatment and therefore reduced likelihood of severe vision loss.

A method of at-home monitoring of eye conditions using a head mounted display that is capable of establishing a visual model associated with a patient. The visual model may include data related to a quality of the patient's vision. The patient may use the system to establish a visual model periodically, such as daily, and the system may compare the visual model to previous visual models and send an alert to the patient's physician if changes meeting a given criteria are detected. This may allow the physician to immediately take steps to save the patient's eyesight where a delay in treatment may result in vision loss.

A nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and / or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, vitamin E, beta-carotene, zinc and copper. The essential ingredients are preferably provided in a tablet form suitable for oral ingestion. Preferably the composition is taken in the form of one or two tablets taken twice daily.

The invention relates to a cellprotective, neuroprotective and retinoprotective composition. In an embodiment of the invention, said composition comprises (i) Ramipril or Ramiprilate and (ii) folic acid. The composition of the invention can be used, in particular, for the prevention of loss of vision, or even for improving visual acuity and visual field in normal subjects, as well as for treating ophthalmologic pathologies, in particular: glaucoma, diabetic retinopathy, age related macular degeneration, hereditary dystrophy of the retina, uveitis, ammetropia (myopia, presbyopia). This combination of active principles could also be used in general conditions for treating general pathologies (cancer...).

A composition for optic nerve cell protection, for preventing or treating glaucoma, for suppressing retinal ganglion cell death, or for delaying a progression of visual acuity loss of human contains at least one selected from the group consisting of products obtained by steaming and drying wheat, defatted wheat germ, defatted rice germ, defatted soybean, fermented grape, hesperidin, lactic acid bacterium Lactobacillus salivarius, wild grape, Tamarind, Haskap, pomegranate seeds, licorice powder, and cinnamon powder.

A system for promoting medication adherence is provided. The system may receive medical information and medication access information via a medication adherence device, the medication adherence devicehaving a housing configured to be removably coupled to a medicine container top and an access switch, the access switch generating medication access information when the housing is uncoupled from themedicine container top. The information may be used to form one or more blind spots which may be representative of symptoms of glaucoma and which may be produced on the display screen of a patient'sclient device. The system may use Gamblification and / or Gamification in which a blind spot obscures portions of a game of chance program and / or novelty game type program, respectively, from being observed on the display screen of the client device. As medical information and medication compliance information is received, the number, size, opacity, and / or shape of the blind spots produced on the display screen of a patient's client device may change to provide actual perception of visual loss which spurs patients to compliance.

The present invention provides a system for improving medication compliance. The system may receive medical information and medication access information through a medication adherence device having a housing and an access switch, the housing configured to be detachably attached to the top of the medication container, when the housing is attached to the medication container When the top is detached, the access switch generates medication access information. This information can be used to form one or more blind spots, which can represent symptoms of glaucoma and can be generated on a display screen of the patient's client device. The system may use gaming and / or gamification in which blind spots block portions of the game of chance and / or game-type programming, respectively, from view on the display screen of the client device. The number, size, opacity, and / or shape of the blind spots created on the display screen of the patient's client device may change to provide an actual perceived loss of vision that stimulates the loss of vision when medical information and medication compliance information is received The patient complies.

A nutritional or dietary supplement composition that strengthens and promotes a general eye health benefit for aging adults, including retinal health through the prevention, stabilization, reversal and / or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts.

Described herein are methods and pharmaceutical compositions for the prevention and / or treatment of visual impairment and vision loss, and more particularly to the use of DAN family BMP antagonist(s) for the prevention of ocular neovascularization and, as a trophic factor for photoreceptors in eye diseases. Also described is a method for long-term inhibition of neovascularization in an ocular condition, a method of replacement therapy for vascular endothelial growth factor (VEGF) inhibitor treatment and a method for inhibiting and / or preventing ocular neovascularization and / or ocular angiogenesis in a mammalian subject, the methods comprising administering to a mammalian subject in need an effective amount a DAN family BMP antagonist such as DAND5.

The present invention provides a reading test to measure vision loss. In one embodiment, the vision loss is due to disease progression. The tests are useful in evaluating the effects of intervention in vision deterioration. The tests are non-invasive, simple, quick, sensitive, reproducible, and easy to administer. The tests measure the subject's reading speed and accuracy under defined conditions of illumination and contrast. The results of these tests may be used to determine if treatment of a disease should be initiated, terminated, altered, or remain unchanged.

A nutritional or dietary supplement composition that strengthens and promotes a general eye health benefit for aging adults, including retinal health through the prevention, stabilization, reversal and / or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts.